NuScale Power Stock Has 107.1% Upside According to This Wall Street Analyst. Is He Right?

Canaccord analyst George Gianarikas reiterated a Buy on NuScale Power with a $25 price target, implying 107.1% upside versus the current share price. The bullish case centers on NuScale's small modular reactor pipeline, TVA and RoPower projects, and long-term commercialization potential, but the article stresses significant execution and operational risks. The piece is more of an analyst commentary than a catalyst, so near-term market impact is likely limited.

Analysis

The market is still underpricing the distinction between a credible technology platform and a bankable commercial franchise. NuScale’s upside is not primarily about reactor economics at the margin; it is about whether one or two reference projects can convert the company from a design story into a financing story. That transition matters because once a utility-grade customer de-risks the technology, the order pipeline can re-rate faster than the fundamentals, but only if schedules hold and counterparties remain intact.

The second-order winner is not necessarily the SMR developer with the best headline design, but the ecosystem that can sell “de-risked nuclear” to hyperscalers, utilities, and sovereigns. If NuScale’s grid-scale approach gains credibility, engineering, procurement, and construction partners, nuclear component suppliers, and uranium-adjacent beneficiaries may see more durable demand than the equity itself. By contrast, the competitive threat to microreactor plays like OKLO is that capital allocators may prefer larger, regulated-basis deployment paths before they fund distributed, site-specific deployments at scale.

The key risk is timing mismatch: the stock can reprice on contract headlines, but dilution risk is driven by multi-year capex, permitting, and financing gaps. If execution slips even one project cycle, the market will likely compress the multiple well before any long-term demand thesis breaks. In that scenario, the real loss is not just project delay; it is the higher cost of capital, which can force equity raises at exactly the wrong time.

Consensus appears too focused on terminal value and not enough on path dependency. A high WACC helps the valuation argument, but it does not eliminate the reflexive risk that each delay raises financing costs and reduces partner appetite. This is a classic “good technology, bad stock” setup until there is hard evidence that commercial conversion is faster than the market expects.

Key Decisions for Investors

• Avoid outright long SMR at current levels; wait for a project-financing milestone or schedule confirmation before initiating risk. If entered on a pullback, size it as a long-dated optionality trade, not a core position.
• Pair trade: long SMR / short OKLO only if you want to express preference for grid-scale utility adoption over microreactor adjacency plays; the trade is thesis-driven but should be hedged tightly because both names are sentiment-sensitive.
• Buy 6-12 month SMR call spreads rather than stock to capture upside from a re-rating while capping dilution and execution downside; structure around the next meaningful partnership or permitting catalyst.
• If you already hold OKLO, trim on any relative strength versus SMR; the market may temporarily reward proximity-to-hyperscaler narratives, but capital may ultimately favor utility-scale deployment first.
• Monitor financing and EPC partner announcements as the real catalyst set; if those are absent over the next 1-2 quarters, expect multiple compression despite positive analyst coverage.